Coupling tissue-type plasminogen activator (tPA) to carrier red blood cells (RBC) prolongs its intravascular life span and permits its use for thromboprophylaxis. Here, we studied the susceptibility of RBC/tPA to PA inhibitors including plasminogen activator inhibitor-1 (PAI-1) that constrain its activity and may reduce the duration of its effect. Despite lesser spatial and diffusional limitations, soluble tPA was far less effective than RBC/tPA in dissolving clots formed in vitro from blood of wildtype (WT) mice (40 versus 80% lysis at equal doses of tPA). Furthermore, after i.v. injection, soluble tPA lost activity faster in transgenic mice expressing a high level of PAI-1 than in WT mice, whereas the activity of RBC/tPA was unaffected. PAI-1 inactivated soluble tPA at equimolar ratios in vitro, but it had no effect on the amidolytic or fibrinolytic activity of RBC/tPA. RBC/ tPA was also more resistant than soluble tPA to in vitro inhibition by other serpins (␣ 2 -macroglobulin and ␣ 1 -antitrypsin) and pathologically high levels of glucose. However, coupling to RBC did not protect a truncated tPA mutant, Retavase, from plasma inhibitors. Chemical removal of the RBC glycocalyx negated tPA protection from inhibitors: tPA coupled to glycocalyx-stripped RBC bound twice as much 125 I-PAI-1 as did tPA coupled to naive RBC, and susceptibility of the bound tPA to inhibition by PAI-1 was restored. Thus, the RBC glycocalyx protects RBC-coupled tPA against inhibition. Resistance to high levels of inhibitors in vivo contributes to the potential utility of RBC/tPA for thromboprophylaxis.
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There is a need for improved treatment and prevention of thrombosis, especially in patients identified as being at high risk for recurrence. Thromboprophylaxis by anticoagulants and platelet inhibitors has been modestly successful, but most patients with myocardial infarction and stroke remain unprotected (Lam et al., 1991; Topol et al., 1999; Jackson et al., 2000; Hennan et al., 2002; Hong et al., 2003; Lange and Hillis, 2004) . Both unfavorable pharmacokinetics and low benefit/risk ratio have precluded the use of plasminogen activators (PAs) in clot prevention. The effectiveness of PAs is limited by clot penetration and their rapid inactivation by plasma inhibitors and clearance from the blood (Verstraete et al., 1985; Lucore and Sobel, 1988; Thomas et al., 1993; Narita et al., 1995; Rijken et al., 2004) . Treatment requires administration of PAs in doses several orders of magnitude above physiological levels to attain therapeutic efficacy, posing a considerable risk of hemorrhage (Ridker et al., 1994) . To date, modifications in the design and delivery of plasminogen activators to attain greater affinity for fibrin, longer circulation time, and greater resistance to inhibitors have been of rather modest clinical benefit (Keyt et al., 1994; Benedict et al., 1995; Liberatore et al., 2003; Rijken et al., 2004; Inoue et al., 2005) .
To be of use in thromboprophylaxis, a fibrinolytic agent should selectively lyse potentially occlusive clots during their formation, without affecting hemostatic clots or exerting extravascular toxicity (Wang et al., 1998; Melchor and Strickland, 2005) . Moreover, to be practical, delivery must be feasible and PA activity must be expressed for hours to days.
However, all existing fibrinolytics are relatively short-lived (Ͻ30 min) and small (Ͻ10 nm in diameter) agents, capable of diffusion into hemostatic clots and the tissues, including the CNS. None can be used as prophylaxis, even in the patients known to be at high risk of imminent or recurrent thrombosis.
Previous studies showed that coupling tPA to red blood cells (RBC) produces long-circulating enzymatically active complexes, thus converting tPA from a therapeutic agent with considerable safety concerns into an effective and safe thromboprophylactic agent (Murciano et al., 2003; Ganguly et al., 2005 Ganguly et al., , 2006 . Injection of either preformed RBC/tPA (Murciano et al., 2003; Ganguly et al., 2005 Ganguly et al., , 2006 or tPA derivatives targeted to complement receptor-1 on circulating RBC (Zaitsev et al., 2006) prevents subsequent formation of occlusive venous and arterial clots, with no overt harmful effects on the carrier RBC (Murciano et al., 2003; Ganguly et al., 2005 , activation of coagulation (Murciano et al., 2003) or impaired postsurgical hemostasis (Zaitsev et al., 2006) .
Of particular interest, previous studies showed that RBC/ tPA lysed human plasma clots more effectively than soluble tPA added to the clots at equal doses despite the obvious diffusional/spatial disadvantage of RBC/tPA (Ganguly et al., 2005) . One possible explanation for this surprising result is that coupling to RBC renders tPA less susceptible to plasma PA inhibitors, including the most physiologically relevant, plasminogen activator inhibitor 1 (PAI-1) (Loskutoff et al., 1989) . Sensitivity to inhibitors is one of the factors that may control the longevity of RBC/tPA activity in vivo and, therefore, the durability of thromboprophylaxis. Plasma levels of PAI-1 are severalfold higher than tPA in healthy subjects and rise further in response to platelet activation (Potter van Loon et al., 1992; Zhu et al., 1999) and vascular injury (Schneiderman et al., 1992; Cesari and Rossi, 1999) . High levels of PAI-1 contribute to the resistance of arterial clots (Potter van Loon et al., 1992; Zhu et al., 1999) and pulmonary emboli to therapeutic lysis (Chapman et al., 1990) . In this study, we investigated the mechanism by which tPA coupled to RBC may be protected against inhibitors.
Materials and Methods
Materials. Human recombinant tPA (alteplase) was from Genentech (South San Francisco, CA) and rPA (reteplase) was from Centocor Inc. (Horsham, PA); plasminogen (Pg) Spectrozyme-tPA and PAI-1 were from American Diagnostica (Greenwich, CT); streptavidin (SA), ␣ 2 -macroglobulin, and ␣ 1 -antitrypsin were from Calbiochem (San Diego, CA); human thrombin, neuraminidase, hyaluronidase, and heparinase were from Sigma-Aldrich (St. Louis, MO); human fibrinogen was from Enzyme Research Laboratories Inc. (South Bend, IN); iodogen and long-chain 6-biotinylaminocaproic acid N-hydroxysuccinimide ester were from Pierce Chemical (Rockford, IL). Noncleavable human plasminogen [NC-Pg (R561A); hereafter called NC-Pg] was expressed in Drosophila S2 cells stably transfected with cDNA encoding a plasmin-resistant mutant of plasminogen (a kind gift from Dr. F. J. Castellino, University of Notre Dame, South Bend, IN). Proteins were radiolabeled with Na( 125 I) (PerkinElmer Life and Analytical Sciences, Boston, MA) using iodogen according to the manufacturer's instructions. Free 125 I was removed using a Biospin 6 column (Bio-Rad, Hercules, CA). Wild-type (WT; C57BL/6J) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Transgenic mice overexpressing a murine PAI-1 minigene (PAI-1Tg ϩ ) under control of a cytomegalovirus promoter, generated as described previously (Eitzman et al., 1996) and crossed greater than 20 generations to C57BL/6J, were the kind gifts of Dr. Ginsburg (University of Michigan, Ann Arbor, MI).
Coupling of tPA to Carrier RBC. RBC were isolated by centrifugation from fresh anticoagulated human and mouse blood. Approximately 6 ϫ 10 4 molecules of tPA were attached per RBC without loss of enzymatic activity or alterations in RBC biocompatibility as described previously (Muzykantov and Murciano, 1996; Murciano et al., 2003; Ganguly et al., 2005 Ganguly et al., , 2006 . Briefly tPA and RBCs (10% hematocrit) were biotinylated with 6-biotinylaminocaproic acid Nhydroxysuccinimide ester at 5-fold molar excess (b 5 tPA) or 10 M (b 10 RBC). Biotinylated RBC were mixed with naive RBC (1:1) to prevent agglutination and then incubated with SA (10 6 molecules/ RBC). Unbound SA was removed by washing the cells three times followed by incubation with radiolabeled b 5 tPA. Unbound tPA was removed by washing, and cell-associated tPA was measured in a gamma counter (PerkinElmer Life and Analytical Sciences) (Murciano et al., 2003; Ganguly et al., 2005 Ganguly et al., , 2006 . The b 10 RBC/b 5 tPA conjugates are henceforth designated as RBC/tPA. In separate experiments, RBCs were incubated for 3 h at 37°C with a mixture of glycocalyx-degrading enzymes: neuraminidase (5 mU/ml), hyaluronidase (5 U/ml), and heparinase (5 U/ml) before biotinylation. Cells were washed three times to remove excess enzyme, biotinylated, and incubated with SA and b 5 tPA as described above.
In Vitro Lysis of Blood Clots Obtained from Mice. Blood was drawn from WT mice in borosilicate tubes without anticoagulant, 125 I-Fg (2 l), and either soluble tPA or tPA coupled to RBC (RBC/ tPA) (10 nM each) was added and incubated for 20 min at room temperature. The release of soluble 125 I-fibrin fragments into the supernatant over the next 6 h at 37°C was measured in a gamma counter (Murciano et al., 2003; Ganguly et al., 2005) .
Ex Vivo Fibrinolytic Activity of RBC/tPA versus Soluble tPA Circulating in Wild-Type and PAI-1-Overexpressing Transgenic Mice. Wild-type (C57BL/6J) and PAI-1 Tg ϩ mice were divided into two groups and injected with either soluble tPA (0.5 mg/kg) or RBC/tPA (0.2 mg/kg) via the jugular vein. Blood (200-l aliquots) was drawn 5 min and 15 min postinjection into borosilicate tubes without anticoagulant, and 2 l of 125 I-Fg was added immediately. The blood was allowed to clot over the next 20 min at room temperature and fibrinolysis was determined by release of radiolabeled fibrin degradation products as described above (Murciano et al., 2003; Ganguly et al., 2005 Ganguly et al., , 2006 . Amidolytic Activity of Soluble PA and RBC/PA in the Presence of PAI-1. Soluble tPA, rPA, RBC/tPA, and RBC/rPA (0.05 M) were preincubated with an equimolar concentration of PAI-1 for 30 min at room temperature followed by incubation with Spectrozyme tPA (0.4 mM). The preparations were incubated with Spectrozyme (final volume 200 l) in V-shaped plates for 20 min at 25°C and centrifuged at 1200g for 2 min to precipitate RBC. The optical density was measured at 405 nm in 100-l aliquots of the supernatants (Ganguly et al., 2005) .
Effect of Plasma PA Inhibitors on Lysis of Fibrin Clots by Soluble PA and RBC/PA. Soluble and RBC/PA (both tPA and rPA) (5 nM) were preincubated with PAI-1, ␣ 2 -macroglobulin, and ␣ 1 -antitrypsin in varying molar ratios (1.0:0.5-4.0) for 30 min at room temperature. Fibrin clots were prepared by adding a trace amount of 125 I-Fg (2 l) to a 3-mg/ml human fibrinogen-containing plasminogen. CaCl 2 and thrombin (final concentrations 20 mM and 0.2 U/ml, respectively) were added, and PBS (200 l) was layered over the clots. Fibrinolytic agents were added to the clots to simulate their proposed in vivo application (Murciano et al., 2003; Ganguly et al., 2005 Ganguly et al., , 2006 . Soluble tPA mixed in PBS (200 l) was added externally onto the clot surface to model therapeutic dissolution of preexisting clots, whereas RBC/tPA was incorporated into the clot to model prophylactic lysis of nascent clots (Ganguly et al., 2005) . Clot lysis was measured by the release of the soluble 125 I-fibrin in the supernatant.
Coupling to RBC Protects tPA against Inhibitors
Binding of 125 I-PAI-1 to tPA Coupled to Naive or Glycocalyx-Stripped RBC. RBC/tPA conjugates prepared using naive or glycocalyx-stripped RBC were incubated with 125 I-PAI-1 at a 1:1 M ratio relative to RBC-coupled tPA for 30 min at room temperature. Unbound 125 I-PAI-1 was removed by washing, and RBC-bound radioactivity was used to calculate the number of PAI-1 molecules bound to RBC/tPA.
Binding of RBC/PA and Glycocalyx-Stripped RBC/PA to Plasminogen. We measured binding of RBC/PA to immobilized proteins as described previously (Ganguly et al. 2005 ). Pg and NC-Pg (0.2 M/well) were immobilized on 24-wells polystyrene plate overnight at 4°C. Protein-coated wells were blocked with PBS-BSA (3%) and incubated with RBC/PA for 20 min at room temperature on a horizontal shaker at a low speed (2g). In a separate series, RBC/PA was incubated in Pg-coated wells in the presence of 0.1 M -aminocaproic acid, a lysine analog that blocked the lysine-binding sites on immobilized Pg. Binding of RBC was quantified by measuring hemoglobin at 405 nm after lysing the bound cells in water as describe previously .
Fibrinolytic Activity of Soluble tPA versus RBC/tPA in Presence of a High Level of Glucose. Soluble tPA or RBC/tPA was incubated with 0, 120, 200, 400, and 600 mg/dl glucose in PBS-BSA for 24 h at 4°C. Lysis of 125 I-fibrin clots was determined as described above. In a separate series of experiments, naive RBC/tPA or glycocalyx-stripped RBC/tPA was incubated with glucose before addition within fibrin clots.
Results
Coupling to RBC Renders tPA Less Susceptible to Plasma Inhibitors. The results of prior studies indicated that RBC/tPA cause less extensive lysis of clots prepared from pure fibrinogen than soluble tPA on a molar basis (Ganguly et al., 2005) , probably because of limitations on diffusion and spatial freedom of tPA imposed by the carrier RBC. Yet, RBC/tPA caused more extensive in vitro lysis of clots formed from human plasma than soluble tPA. These seemingly discrepant observations implied that coupling to RBC in some way enhances the resistance of tPA to plasma inhibitors, such as PAI-1.
We first evaluated the relative resistance of RBC/tPA versus tPA to inhibition in vivo by injecting these formulations intravenously in WT and PAI-1 Tg ϩ mice. The plasma level of PAI-1 averages Ͻ0.8 ng/ml in WT mice versus 30 ng/ml in PAI-1 Tg ϩ mice (Eitzman et al., 1996) ; hence, this study also tested whether enhanced resistance of RBC/tPA to PAI-1 is evident in the pathological settings associated with elevated levels of the inhibitor. Blood was drawn and allowed to clot in the presence of 125 I-fibrinogen, and then clot lysis was determined ( Fig. 1) . Previous studies showed that the half-life of radiolabeled RBC/tPA in mice is Ͼ3 h versus Ͻ15 min for soluble tPA (Ganguly et al., 2005) . Therefore, mice were injected with either 0.5 mg/kg soluble tPA or 0.2 mg/kg RBC/ tPA, and blood was drawn at 5 and at 15 min to compensate for the rapid clearance of soluble tPA.
After a 6-h incubation at 37°C, clots formed from the blood of WT and PAI-1 Tg ϩ mice underwent 15.9 Ϯ 0.8% (Fig. 1 , dashed line baseline) and 12.6 Ϯ 1.3% spontaneous lysis, respectively. Five minutes after injection of tPA, clot lysis rose to 60.2 Ϯ 2.7% in WT mice versus 33.8 Ϯ 5.6% in PAI-1 Tg ϩ mice (p Ͻ 0.05). Within 15 min of injection, soluble tPA exhibited a markedly decreased fibrinolytic capacity, which remained close to baseline in both WT and PAI Tg ϩ mice (Fig. 1B) . In contrast, RBC/tPA retained very similar activity in WT and PAI-1 Tg ϩ mice at both 5 and 15 min after injection (87.9 Ϯ 6.7 versus 75.7 Ϯ 12.4% and 75.19 Ϯ 9.5 versus 63.2 Ϯ 5.2% at 5 and 15 min, respectively). Thus, in contrast to soluble tPA, RBC/tPA is relatively resistant to highly elevated levels of PAI-1 in vivo.
To exclude the pharmacokinetic effects, we compared lysis by the same concentration (10 nM) of RBC/tPA versus tPA added directly to blood drawn from WT mice before clotting in vitro. Despite being subject to fewer spatial constraints, soluble tPA caused less than 50% as much fibrinolysis as RBC/tPA in the blood of WT mice (41.1 Ϯ 9.3 versus 83.3 Ϯ 2.4%, respectively). These data 1) affirm the greater fibrinolytic potency of RBC/tPA compared with soluble tPA in mouse blood in vitro and in vivo, and 2) indicate that coupling to RBC protects tPA against physiological and pathological concentrations of PAI-1.
RBC/tPA Is Less Susceptible to Diverse PA Inhibitors Than Soluble tPA. We next compared the susceptibility of soluble tPA versus RBC/tPA and soluble rPA versus RBC/rPA to various purified plasma PA inhibitors. Equimolar concentrations of PAI-1 caused almost complete loss of tPA-mediated chromogenic ( Fig. 2A) and fibrinolytic (Fig.  2B ) activity, whereas neither activity of RBC/tPA was affected under the same experimental conditions (Fig. 2, left) . However, coupling of rPA to RBC provided little protection of its amidolytic activity (Fig. 2C ) and no protection of its fibrinolytic activity (Fig. 2D ) from inhibition by PAI-1. Likewise, equimolar concentrations of two plasma serpins with broad spectrum of inhibition, ␣ 2 -macroglobulin and ␣ 1 -antitrypsin, suppressed the fibrinolytic activity of soluble tPA but not RBC/tPA (Fig. 3) . Again, coupling of rPA to RBC did not protect its fibrinolytic activity against inhibition by ␣ 2 -macroglobulin (53.2 Ϯ 2.1 and 52.5 Ϯ 12.7% inhibition of rPA and RBC/rPA, respectively) or ␣ 1 -antitrypsin (24.9 Ϯ 8.7 and 48.8 Ϯ 12.1% inhibition of rPA and RBC/rPA, respectively).
The RBC Glycocalyx Protects Coupled tPA from Plasma Serpins. The enhanced resistance of RBC-coupled tPA to plasma inhibitors could result from conformational changes in the tPA molecule caused by conjugation and/or its masking by RBC glycocalyx. To study the mechanism in greater detail, we coupled tPA to RBCs that had been preincubated with a mixture of glycocalyx-degrading enzymes (heparinase, neuraminidase, and hyaluronidase) and tested the susceptibility of the resulting RBC/tPA to serpins. Equimolar amounts of inhibitors were added relative to the amount of RBC-bound tPA determined using 125 I-tPA (6 Ϯ 0.2 ϫ 10 4 and 3.2 Ϯ 0.1 ϫ 10 4 tPA molecules per naive and glycocalyx-stripped RBC, respectively). tPA coupled to RBC or glycocalyx-stripped RBC exhibited similar amidolytic (e.g., A 405 equal 0.90 Ϯ 0.03 in RBC/tPA versus 0.91 Ϯ 0.26 in stripped RBC/tPA in the Spectrozyme assay) and fibrinolytic activity (Fig. 4A) . However, coupling tPA to glycocalyx-stripped RBC did not confer the enzyme with enhanced resistance to PAI-1, ␣ 2 -macroglobulin, or ␣ 1 -antitrypsin (Fig. 4A) . In support of this inference, binding of 125 I-labeled PAI-1 to tPA coupled to glycocalyx-stripped RBC almost doubled compared with binding to tPA coupled to control RBC (Fig. 4B) . These data suggest that the RBC glycocalyx protects cell-bound tPA against plasma serpins by masking their auxiliary binding sites (Carrell et al., 1991; Lawrence et al., 1995; Wilczynska et al., 1995) .
Stripping of RBC Glycocalyx Does Not Affect the Binding of RBC/tPA to Plasminogen. We next tested whether RBC glycocalyx also affects the interaction of RBCbound tPA with its physiological substrate, plasminogen. RBC/tPA but not RBC/rPA bound to plastic wells coated with Pg (Fig. 5) . Naive RBC showed no binding to Pg (Fig. 5,  dashed line) , confirming specificity of RBC/tPA binding. Fur- thermore, RBC/tPA showed no binding in albumin-coated wells (Fig. 5, inset) . RBC/tPA binding to Pg was blocked by the lysine analog, i.e., -aminocaproic acid or by replacing Pg with its noncleavable analog NC-Pg (Fig. 5) , indicating that binding requires interactions between Lys binding sites in plasminogen activators and Lys residues in the substrate. However, RBC/tPA and stripped RBC/tPA bound to plasminogen to a similar extent (28.3 Ϯ 3.1 ϫ 10 3 versus 25.2 Ϯ 4.9 ϫ 10 3 RBCs/well, respectively). Coupling to RBC Protects tPA against Inhibition by High Levels of Glucose. Pathologically high levels of glucose have also been shown to inhibit tPA activity (AlvarezSabin et al., 2004) . Therefore, we next tested whether coupling to RBC alters susceptibility of tPA to elevated levels of glucose. Addition of pathologically high levels of glucose (600 mg/dl) directly to fibrin clots along with tPA did not affect either spontaneous lysis or lysis induced by RBC/tPA or soluble tPA (Fig. 6A, inset) . These data corroborate findings that tPA inhibition via nonenzymatic glycosylation/glycation requires a relatively prolonged (i.e., hours) exposure (Lapolla et al., 2005) .
Preincubation with glucose at high concentrations for 24 h markedly inhibited the fibrinolytic activity of soluble tPA, but not RBC/tPA (Fig. 6A) . Furthermore, tPA coupled to glycocalyx-stripped RBC was less resistant to the inhibitory effect of glycation than tPA coupled to naive control RBC (Fig. 6B ). These data imply that, in addition to masking binding sites for protein inhibitors (Fig. 4B) , the RBC glyco- Fig. 4 . RBC glycocalyx protects RBC/tPA from plasma inhibitors. RBCs were incubated with a cocktail of neuraminidase, hyaluronidase, and heparinase to remove the glycocalyx and then conjugated with tPA. Two RBC/tPA formulations were tested: tPA coupled to naive RBC (RBC/tPA; black bars) and tPA coupled to the glycocalyx-stripped RBC (stripped RBC/tPA; hatched bars). Both types of RBC/tPA complexes were incubated with PAI-1(1:1), ␣ 2 -macroglobulin (1:2), or ␣ 1 -antitrypsin (1:2) at indicated molar ratios before incorporation within fibrin clots. A, effect of inhibitors on lysis of 125 I-fibrin clots. B, binding of 125 I-PAI-1 to naive versus glycocalyx-stripped RBC/tPA. The RBC/tPA complexes were incubated with 125 I-PAI-1 at a 1:1 M ratio relative to bound tPA for 30 min at room temperature. Unbound 125 I-PAI-1 was removed by washing and residual radioactivity measured. Data are mean Ϯ S.D. (n ϭ 3). Differences between the groups are significant: ‫,ءء‬ p Ͻ 0.01. calyx exerts a more general stabilizing effect on tPA molecule.
Discussion
The fibrinolytic activity of tPA in plasma is regulated primarily by diffusion-limited inactivation by the suicide substrate PAI-1 and to a lesser extent by other plasma serpins such as ␣ 1 -antitrypsin, ␣ 2 -macroglobulin, and C1 inhibitor (Madison et al., 1990; Chandler et al., 1995) . PAI-1 traps tPA in the form of an inactive, stabilized acyl enzyme intermediate (1:1 complex) (Carrell et al., 1991; Lawrence et al., 1995) that is cleared from plasma with a half-life of 3 to 5 min by the low-density lipoprotein-related receptor and the very lowdensity lipoprotein receptor (Bu et al., 1992) , leading to degradation of the enzyme in lysosomes. Increased expression of PAI-1 by ischemic endothelium and release from activated platelets contributes to the resistance of platelet-rich arterial thrombi to lysis (Zhu et al., 1999) .
In part to compensate for rapid inactivation and clearance, tPA must be given at concentrations several orders of magnitude higher than physiological concentrations to mediate reperfusion after myocardial infarction or stroke (Ridker et al., 1994) . The need for such high doses for efficacy is accompanied by a considerable risk of hemorrhage. Genetic reengineering of tPA to remove critical auxiliary sites that help mediate serpin binding (amino acids 296 -304) increases the resistance of the molecule to PAI-1 (Madison et al., 1990) and prolongs its circulation in plasma (e.g., TNKase mutant) (Keyt et al., 1994) , but not to the extent needed to provide thromboprophylaxis. Moreover, TNKase, like other tPA variants, is a relatively small (ϳ60-kDa) protein capable of diffusing into preexisting hemostatic clots and through bloodbrain barrier perturbed by ischemia into brain parenchyma, hence increasing the risk of hemorrhages and other adverse effects.
Results of the previous studies have shown that coupling tPA to carrier RBC increases its intravascular life span by several orders of magnitude compared with soluble tPA (Murciano et al., 2003; Ganguly et al., 2005) and that it restricts PA extravasation into brain (Murciano et al., 2003) . During the course of this study, RBC/tPA was found to be less active than soluble tPA in lysing clots formed from fibrinogen, probably because of steric constraints on permeation, but it showed clear fibrin specificity (Ganguly et al., 2005) , and surprisingly, it was more active than soluble tPA in lysing clots made from human plasma (Ganguly et al., 2005) . These findings suggested a fundamental change in the relationship between tPA-mediated plasminogen activation and inhibition by cognate serpins that results from coupling the enzyme to the cell surface.
The present study shows that the protection afforded by RBC binding is dependent on the glycocalyx of the cell. Enzymatic degradation of the glycocalyx did not affect basal amidolytic (0.90 Ϯ 0.03 in RBC/tPA versus 0.91 Ϯ 0.26 in stripped RBC/tPA) or fibrinolytic activity of RBC-coupled tPA (Fig. 4A) . However, removal of the glycocalyx led to the loss of protection of tPA by RBC, both in terms of PAI-1 binding and tPA activity. These results do not exclude that a change in conformation of tPA imposed by conjugation contribute to protection but favor a more specific effect of the glycocalyx on PAI-1 binding to the auxiliary sites on tPA, access to tPA catalytic site, or restrictions on conformational changes in PAI-1 that occur after binding (Carrell et al., 1991; Lawrence et al., 1995; Wilczynska et al., 1995; Egelund et al., 2001) .
The RBC glycocalyx affects the interaction of RBC-bound tPA with its inhibitors, activators (e.g., fibrin), and substrates (physiological substrate, plasminogen, and small synthetic substrates used to measure amidolytic activity) in a complex, but precise way. Our previous studies showed that coupling to RBC does not affect the stimulation of tPA activation by fibrin (Ganguly et al. 2005) . The results of the present study indicate that the RBC glycocalyx does not affect RBC/tPA binding to plasminogen (Fig. 5) . Therefore, it seems that coupling to RBC does not compromise tPA interactions with its substrates and activators; yet, coupling protects it from the inhibitors.
It is known that cellular glycocalyx may affect the activity of plasmin (Pluskota et al., 2004) . Therefore, in theory, the enhanced activity of RBC/tPA seen in the presence of inhibitors could be due to protection of plasmin. However, coupling to RBC did not protect a truncated form of tPA, rPA, against plasma inhibitors (Fig. 2) . This selectivity argues for a direct effect of the RBC glycocalyx on tPA. This interpretation is supported by the fact that the RBC glycocalyx protects the amidolytic activity of tPA as well.
It is not clear yet why RBC does not protect rPA. In theory, this result can be explained by 1) lack of auxiliary sites for interactions with glycocalyx or/and inhibitors on the rPA molecule that lacks the finger, growth factor, and Kringle-1 domains present in tPA; and/or 2) unique conformational changes caused in rPA as a result of conjugation. It is an interesting corollary in this context that despite the fact that RBC/tPA and RBC/rPA possess equal activity in the absence of inhibitors (indicating that they interact equally well with plasminogen and convert it to plasmin), only RBC/tPA possess sufficient affinity to plasminogen to afford specific binding via lysine-mediated mechanism (Fig. 5 ).
Understanding the mechanism by which the glycocalyx protects tPA from PAI-1 and other serpins will require additional studies. The most simplistic explanation that the glycocalyx physically masks the auxiliary binding site(s) for PAI-1 seems less likely based on the selective effect in this tPA feature with no effect on the enzyme access to plasminogen or fibrin. Rather, specific "protection" of tPA by RBC glycocalyx against serpins may be explained by interference with charge-mediated interactions between the protease and protein inhibitor. It seems likely that PAI-1 contacts with the surface loop of tPA via residues 350 to 355, which contains several negatively charged amino acids (Glu-Glu-Ile-ILeMet-Asp) (Madison et al., 1990) . The interaction of tPA and PAI-1 may therefore be stabilized through salt bridges formed between cationic amino acids tPA and anionic residues in PAI-1 (Madison et al., 1990; Egelund et al., 2001) . Negatively charged components of RBC glycocalyx such as ionized sialic acid groups may impede these interactions by forming an electrostatic as well as a physical barrier between protease and serpins.
The observation that the RBC glycocalyx also protects tPA against inactivation by nonenzymatic glycosylation may support the notion that protection is due to charge-mediated masking of vulnerable sites on tPA molecules by the glycocalyx. Interactions between RBC/tPA and the glycocalyx may jpet.aspetjournals.org mask the lysine residues in tPA molecules that are vulnerable to Maillard product formation and glycation (Lapolla et al., 2005) .
The finding that RBC-bound tPA is more resistant to PAI-1 and other serpins and high levels of glucose translates into additional practical advantages for this modality. These include reduction in the effective dose with attendant lessening of the risk of hemorrhage, extended duration of thromboprophylaxis, enhanced effectiveness toward platelet-rich arterial clots and prevention of thrombosis in diabetics. The results of this study also reveal a relatively unappreciated role for the glycocalyx in modulating tPA activity, which may take place on the surface of endothelial, hematopoietic, and other vascular cell types, that deserves greater scrutiny.
